MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the start of patient enrollment in the ev3 DEFINITIVE™ AR (Anti-Restenosis) study Imelda Hospital in Belgium with Dr. Patrick Peeters.
